Apr 4 |
After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study
|
Apr 4 |
Candel stock soars on positive data from mid-stage pancreatic cancer drug trial
|
Apr 4 |
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
|
Mar 28 |
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
|
Mar 28 |
Candel Therapeutics GAAP EPS of -$0.38
|
Mar 28 |
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
|
Mar 5 |
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
|
Feb 13 |
Krystal Biotech, Candel, Edgewise gain after FDA fast track tags
|
Feb 13 |
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
|
Feb 5 |
Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
|